This study is looking into how well a new treatment called Alpha DaRT224 works for people with recurrent cutaneous squamous cell carcinoma (cSCC), a type of skin cancer that comes back after treatment. The treatment uses special seeds placed in the tumor, releasing radiation to target cancer cells. About 86 participants will be involved, and the study will track their response to the treatment over six months. The main goals are to see how many patients respond to the treatment and how long this response lasts.

Participants need to have a single tumor no larger than 7 cm and undergo a CT scan. They must have tried other standard treatments without success. The study will also check the safety of DaRT by observing any side effects. It is important for participants to be 18 or older and able to give informed consent. They also need to use birth control during the study if they are of reproductive age.

• Study duration: up to 6 months for response tracking.
• Participants: 86 people with recurrent cSCC.
• Eligibility: single tumor, no larger than 7 cm, unsuccessful prior treatments.